Immunogenic HER-2/neu peptides as tumor vaccines (Q36158153)

12 August 2017

1 reference

title

Immunogenic HER-2/neu peptides as tumor vaccines (English)

1 reference

12 August 2017

Constantin N Baxevanis

1

1 reference

12 August 2017

Nectaria N Sotiriadou

2

1 reference

12 August 2017

Angelos D Gritzapis

3

1 reference

12 August 2017

Panagiota A Sotiropoulou

4

1 reference

12 August 2017

Sonia A Perez

5

1 reference

12 August 2017

Nike T Cacoullos

6

1 reference

12 August 2017

Michael Papamichail

7

1 reference

12 August 2017

27 October 2005

1 reference

Cancer Immunology, Immunotherapy

12 August 2017

1 reference

12 August 2017

55

1 reference

12 August 2017

1

1 reference

12 August 2017

85-95

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-005-0692-3

12 August 2017

0 references

cites work

Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Identification of novel survivin-derived CTL epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0692-3

10.1007/S00262-005-0692-3

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference